Predictive and prognostic factors in RCC

Location: Room 7, Capital suite (level 3)

Chairs: A. Mattei, Luzern (CH)  
M. Oya, Tokyo (JP)  
B. Peyronnet, Rennes (FR)

Aims and objectives of this session
To discuss various predictive and prognostic factors in RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

640

Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study
Institutes: Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Incheon, South Korea, St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Dept. of Urology, Bucheon, South Korea, Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, Chungbuk National University College of Medicine, Cheongju, Korea, Dept. of Urology, Cheongju, South Korea, Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea, College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

641

Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis
By: Larcher A.1, Muttin F.1, Nini A.1, Trevisani F.1, Ripa F.1, Cianflone F.1, Carenci C.1, Dell’Oglio P.1, Rigatti P.2, Dehó F.1, Montorsì F.1, Capitanio U.1, Bertini R.1
Institutes: IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Milan, Italy, Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

642

External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus
Institutes: Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, University Vita-Salute, Dept. of Urology, Milan, Italy, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, University of Miami, Dept. of Urology, Miami, United States of America, University of Southern California, Dept. of Urology, Los Angeles, United States of America, University of California-Davis, Dept. of Urology, Sacramento, United States of America, University of Turin, Dept. of Urology, Turin, Italy, University of Frankfurt, Dept. of Urology, Frankfurt, Germany, University of Heidelberg, Dept. of Urology, Heidelberg, Germany, New York University School of Medicine, Dept. of Urology, New York, United States of America.
The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S.¹, Hsu R.², Blick C.³, Goh V.³, Hanbury D.⁴, Nathan P.⁵, Nicol D.⁶, Fleming S.⁷, Sweeting M.⁸, Watson C.⁹, Wilson E.¹⁰, Stewart G.¹

Institutes: ¹Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ²Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ³Guy’s & St Thomas' Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, ⁴Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ⁵Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, ⁶Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ⁷Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, ⁸University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, ⁹National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, ¹⁰University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma

By: Pecoraro A.¹, Larcher A.¹, Nini A.¹, Mutton F.¹, di Trapani E.¹, Carenzi C.¹, Trevisani F.¹, De Cobelli F.², Gabardi F.¹, Guazzoni G.³, Briganti A.¹, Montorsi F.¹, Bertini R.¹, Capitanio U.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, ³Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients


Institutes: ¹University Hospital Mainz, Dept. of Urology, Mainz, Germany, ²University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴Instituto Nacional De Cancerologia, Dept. of Urology, Mexico, Mexico, ⁵Carl-Thiem–Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, ⁶Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁷University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, ⁸Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ⁹Julius–Maximilians–University Medical Centre of Würzburg, Dept. of Urology, Würzburg, Germany, ¹⁰University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ¹¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹²University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, ¹³Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, ¹⁴Charles University In Pilsen, Dept. of Urology, Pilsen, Czech Republic, ¹⁵Medical University Graz, Dept. of Urology, Graz, Austria, ¹⁶Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, ¹⁷Ludwig–Maximilians–University, Dept. of Urology, Munich, Germany

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease

By: Wagener N.¹, Edelmann D.², Benner A.³, Huck N.¹, Hutterer G.³, Zigeuner R.³, Borgmann H.⁴, Haferkamp A.³, Pahernik S.³, Wolff I.³, Krabbe L.M.¹, Herrmann E.¹, Vergho D.⁴, Mirvald C.³, Surcel C.³
Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S., Beisland C., Gudmundsson E., Stewart G., Lam T., Gietzmann W., Zakikhani P., Marconi L., Williams S., Powles T., Van Werkhoven E., Meijer R., Ljungberg B., Bex A.

Institutes: Lund University, Dept. of Clinical Sciences, Malmö, Sweden; Haukeland University Hospital, Dept. of Urology, Bergen, Norway; Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland; University of Cambridge, Academic Urology Group, Cambridge, United Kingdom; University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom; Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom; Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal; Queen Mary University of London, Barts Cancer Institute, London, United Kingdom; The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands; The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands; Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden; University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands; University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom.

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis


Institutes: Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America; Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America; Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America; Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America; University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany; Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America.

Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America.

Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell
carcinoma
Institutes: 1Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, 2Saitama Cancer Center, Dept. of Urology, Saitama, Japan, 3Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 4Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, 5Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

Utility of chest x-ray in follow-up of pT1 renal cell carcinoma
By: Rizzo M.1, Umari P.1, Pavan N.1, Liguori G.1, Verzotti E.1, Cancellieri L.1, Mottria A.2, Minervini A.3, Trombetta C.3
Institutes: 1Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, 2Onze-Lieve-Vrouwziekenhuis, Dept. of Urology, Aalst, Belgium, 3University Hospital Careggi, Dept. of Urology, Florence, Italy

Organ confined renal cell carcinoma - are the current guidelines sufficient?
By: Frees S.1, Kamal M.1, Nestler S.2, Bidnur S.3, Neisius A.1, Jaeger W.1, Thomas C.1, Thuroff J.4, Roos F.1
Institutes: 1University Medical Center, Dept. of Urology, Mainz, Germany, 2Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, 3Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, 4University Medical Center, Dept. of Urology, Mannheim, Germany

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study
By: Tondut L.1, Peyronnet B.1, Bernhard J-C.2, Vaessen C.2, Doumerc N.4, Sebe P.5, Pradere B.6, Guillonneau B.5, Nouhaud F.X.7, Brichart N.6, Alimi Q.1, Beauval J-B.4, Rammal A.8, De La Taille A.10, Baumert H.11, Droupy S.12, Bruyere F.9, Roupret M.3, Mejean A.13, Bensalah K.1

Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data
By: Camp C.1, O’Hara J.1, Hughes D.1, Adshead J.2
Institutes: 1Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, 2Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom